Alpha Tau Medical Announces Positive Interim Results from U.S. REGAIN Trial for Recurrent Glioblastoma
11/15/2026
Impact: 65
Healthcare
Alpha Tau Medical reported interim results from its U.S. REGAIN trial of Alpha DaRT for recurrent glioblastoma: all eight treated patients were alive as of November 11, 2026. Among six evaluable patients, the objective response rate was 100%, with five complete responses and one partial response, after a median follow-up of 6.9 months. The trial met its feasibility and safety endpoints, with successful deployment in all patients and no unanticipated serious adverse events. The company plans to discuss the results on a November 16 conference call; the article did not report financial results or a stock-price move.
AI summary, not financial advice
Share: